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Assessment of Antibiotic De-escalation by Spectrum Score 
in Patients With Nosocomial Pneumonia: A Single-Center, 
Retrospective Cohort Study
Dan Ilges,1,  David J. Ritchie,1,2 Tamara Krekel,1 Elizabeth A. Neuner,1 Nicholas Hampton,3 Marin H. Kollef,4 and Scott Micek1,2 
1Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA, 2Department of Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, Missouri, USA, 3Center for 
Clinical Excellence, BJC HealthCare, St. Louis, Missouri, USA, 4Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA 
Background. Hospital-acquired and ventilator-associated pneumonia (HAP/VAP) cause significant mortality. Guidelines rec-
ommend empiric broad-spectrum antibiotics followed by de-escalation (DE). This study sought to assess the impact of DE on treat-
ment failure.
Methods. This single-center retrospective cohort study screened all adult patients with a discharge diagnosis code for pneu-
monia from 2016 to 2019. Patients were enrolled if they met predefined criteria for HAP/VAP ≥48 hours after admission. Date of 
pneumonia diagnosis was defined as day 0. Spectrum scores were calculated, and DE was defined as a score reduction on day 3 versus 
day 1. Patients with DE were compared to patients with no de-escalation (NDE). The primary outcome was composite treatment 
failure, defined as all-cause mortality or readmission for pneumonia within 30 days of diagnosis.
Results. Of 11 860 admissions screened, 1812 unique patient-admissions were included (1102 HAP, 710 VAP). Fewer patients 
received DE (876 DE vs 1026 NDE). Groups were well matched at baseline, although more patients receiving DE had respiratory cul-
tures ordered (56.6% vs 50.6%, P = .011). There was no difference in composite treatment failure (35.0% DE vs 33.8% NDE, P = .604). 
De-escalation was not associated with treatment failure on multivariable Cox regression analysis (hazard ratio, 1.13; 95% confidence 
interval, 0.96–1.33). Patients receiving DE had fewer antibiotic days (median 9 vs 11, P < .0001), episodes of Clostridioides difficile 
infection (2.2% vs 3.8%, P = .046), and hospital days (median 20 vs 22 days, P = .006).
Conclusions. De-escalation and NDE resulted in similar rates of 30-day treatment failure; however, DE was associated with 
fewer antibiotic days, episodes of C difficile infection, and days of hospitalization.
Keywords. antibiotic de-escalation; hospital-acquired pneumonia; nosocomial pneumonia; spectrum score; ventilator-
associated pneumonia.
Hospital-acquired pneumonia (HAP) is the most common 
hospital-acquired infection, accounting for 22% of all noso-
comial infections [1]. Mortality rates for HAP and ventilator-
acquired pneumonia (VAP) are high, ranging from 20% to 
60% [2]. Inappropriate initial antimicrobial therapy is asso-
ciated with increased mortality in patients with pneumonia, 
highlighting the need for initial broad-spectrum therapy [3]. 
The 2016 Infectious Diseases Society of America and American 
Thoracic Society guidelines recommend broad empiric cov-
erage for patients with HAP and VAP, including treatment 
for methicillin-resistant Staphylococcus aureus (MRSA) and 
Pseudomonas aeruginosa (PSAR), followed by antibiotic de-es-
calation (DE) [2].
De-escalation refers to narrowing antimicrobial therapy, in-
cluding complete cessation of antibiotics, to target likely patho-
gens while limiting activity against non-pathogenic flora [4]. 
Risks associated with prolonged and/or unnecessary antibiotic 
use are well documented. These include increased development 
of antimicrobial resistance, increased antibiotic adverse effects, 
and increased risk of Clostridioides difficile infection [4, 5]. 
Excess use of antibiotics has also been linked to more days in 
the intensive care unit (ICU) and a longer duration of hospital-
ization overall [6].
Defining DE for the purpose of research has proved chal-
lenging [7]. For this reason, many studies use qualitative meas-
ures, defining DE as the cessation of anti-MRSA coverage, 
anti-PSAR coverage, or both [8, 9]. However, these strategies 
neglect the full spectrum of activity provided by an antibiotic 
regimen, which can have important implications for both the 
human microbiome and local resistance patterns [10, 11]. In 
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been developed that approximate the antimicrobial spectrum of 
a given agent, although the methodology for calculating such 
scores can become burdensome [12–14]. Gerber et al [15] de-
veloped a simple spectrum score, described as an antibiotic 
spectrum index (ASI). This method proved to be useful in as-
sessing the impact of a stewardship intervention aimed at re-
ducing the use of broad-spectrum antibiotics in the treatment 
of community-acquired pneumonia [15]. The purpose of this 
study was to evaluate the impact of DE, defined using a modi-
fied version of the ASI, on outcomes of patients with HAP/VAP.
METHODS
Study Design and Patient Population
This study was a retrospective cohort study of patients admitted 
to Barnes-Jewish Hospital, a 1300-bed academic medical center 
in St. Louis, Missouri, from January 1, 2016 to December 31, 
2019. The study was approved by the Washington University in-
stitutional review board (IRB no. 2018801189) without the need 
to obtain informed consent. All adult admissions coded with an 
International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) or International Classification of 
Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) 
discharge diagnosis code for pneumonia during the study 
period of interest were screened for inclusion (Supplementary 
Appendix). Patients were enrolled if they met predefined cri-
teria for HAP or VAP, which included the following: (1) index 
date of infection onset ≥48 hours after hospital admission for 
HAP or ≥48 hours after initiation of mechanical ventilation for 
VAP, (2) chest radiograph completed within ± 24 hours of index 
pneumonia date, (3) active orders for either anti-MRSA or anti-
PSAR antibiotics, and (4) at least 1 sign of infection, including 
a white blood cell count ≥11 or ≤4 × 109 cells/L, or temperature 
≥38 or ≤36°C [8, 16–18]. To further support the diagnosis of 
pneumonia, a random sample of patients had their chest radio-
graphs reviewed by an investigator (M. H. K.) blinded to group 
allocation, which demonstrated >95% agreement with the pres-
ence of radiographic infiltrates that could be consistent with 
pneumonia. Only the first eligible admission for a given patient 
was included. Patients were excluded if they discharged or died 
before day 3 or if they met criteria for pneumonia within 48 
hours of hospital admission. The index date of pneumonia di-
agnosis was defined as day 0 (Figure 1).
All pharmacy-verified intravenous and oral antibiotic orders 
of interest were captured for each day of admission. Oral vanco-
mycin, oral sulfamethoxazole/trimethoprim, and intravenous 
daptomycin orders were excluded. Spectrum scores were com-
puted using a modified version of the ASI, adopted from Gerber 
et al [15] (Supplementary Table 1). Scores were calculated for 
antibiotics ordered on day 0 and for each successive day after 
Assessment of  composite treatment
failure: all-cause mortality or readmission
for pneumonia







Admission Day –1 Day 0 Day 1 Day 2 Day 3 Day 4 Day 8 Day 9 Day 30
∆ Spectrum score
11860 admissions screened from 9717
patients with ICD-9/10 discharge
diagnosis codes for pneumonia
1812 patients
included
Group 1: DE 786
445 Patients HAP
341 Patients VAP
Group 2: NDE 1026
657 Patients HAP
369 Patients VAP
7671 did not meet pneumonia criteria
         WBC, temperature, or chest X-ray
1619 met pneumonia criteria within 48 hours
529 not on anti-MRSA or anti-PSAR abx on day 1
206 discharged/expired before day 3
23 repeat admissions
10048 admissions excluded
Figure 1. Study schematic and flow diagram. Abx, antibiotics; DE, de-escalation; HAP, hospital-acquired pneumonia; ICD, International Classification of Diseases; MRSA, 
methicillin-resistant Staphylococcus aureus; NDE, no de-escalation; PSAR, Pseudomonas aeruginosa; RE, re-escalation; Temp, temperature; VAP, ventilator-associated 
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the index date of pneumonia diagnosis. When multiple anti-
biotics were ordered, the spectrum scores of the respective 
agents were summed into a composite score. For example, a 
patient on vancomycin and cefepime received a score of 12 (7 
points for cefepime; 5 for vancomycin). The Acute Physiologic 
Assessment and Chronic Health Evaluation (APACHE) II score, 
modified to exclude the Glasgow Coma Scale score, was used to 
assess baseline severity of illness on admission. The Charlson 
comorbidity index (CCI) was calculated using methods previ-
ously described [19] to assess comorbidities at baseline. Orders 
for immunosuppressive medications were queried during 
the index admission and up to 30 days prior (Supplementary 
Appendix). Vasopressor orders queried included norepineph-
rine, vasopressin, and dobutamine. Creatinine clearance was es-
timated each day by the Cockcroft-Gault formula based on the 
highest serum creatinine value available.
Microbiologic data, including respiratory cultures, respi-
ratory viral polymerase chain reaction tests, MRSA nasal cul-
ture swabs, and blood cultures, were collected from days –1 
to 3 of index pneumonia diagnosis (Figure 1). Respiratory 
cultures were classified as sputum-like specimens, which in-
cluded sputum and tracheal aspirates, and bronchoscopy spe-
cimens, which included bronchoalveolar lavage, washings, 
and brushings. Respiratory samples identified as positive for a 
likely pathogen excluded those with only yeast, fungal struc-
tural elements, and/or clinically insignificant flora. Blood cul-
tures identified as positive for a likely pathogen excluded those 
with only coagulase-negative Staphylococci. Additional micro-
biological testing and reporting information is available in the 
Supplementary Appendix.
Outcomes
Patients were divided into 2 groups based on whether or not an-
tibiotic DE occurred, which was defined as a reduction in spec-
trum score on day 3 compared with day 1 [13]. Patients with 
no change or an increase in spectrum score on day 3 compared 
to day 1 were classified as no de-escalation (NDE). Assessment 
of DE on day 3 was chosen to allow time for culture and sus-
ceptibility testing and for medical teams to respond to culture 
results.
The primary outcome was a composite of all-cause mortality 
or readmission for pneumonia within 30 days of pneumonia di-
agnosis. Secondary outcomes included the individual compo-
nents of the primary outcome, as well as 14-day mortality, total 
hospital length of stay, ICU days, ventilator-free days, new va-
sopressor initiation, new onset C difficile infection up to 90 days 
postadmission, antibiotic days, treatment re-escalation, and de-
velopment of acute kidney injury (AKI). Antibiotic days were 
calculated as the number of days that each patient had study 
antibiotics ordered from day 0 to 28. Treatment re-escalation 
was defined as an increase in spectrum score on or after day 
8 to a value greater than the highest score on days 3 to 7 of 
hospitalization. Acute kidney injury was defined using serum 
creatinine according to the Kidney Disease—Improving Global 
Outcomes guidelines [20]. Baseline serum creatinine was de-
fined as the maximum creatinine value on day 0.
Statistical Analysis
Baseline characteristics are presented using descriptive sta-
tistics. Categorical variables were compared using the χ2 test. 
Continuous variables were assessed for normality and com-
pared using the Student t test or Mann-Whitney U test, as ap-
propriate. The composite outcome of 30-day all-cause mortality 
or readmission for pneumonia was assessed using a log-rank 
test and Kaplan-Meier survival curve. To help control for con-
founding variables, predictors of the primary composite out-
come were determined using a multivariable Cox regression 
analysis. De-escalation status, characteristics that were statis-
tically significant on bivariate analysis (P < .05), and factors 
known to influence mortality were considered for inclusion in 
the model. Number of vasopressors (from 0 to 3) and ventilator 
status (yes/no) for days 0 through 3 were also included in the 
model, because these variables often influence clinical decision 
making with regards to antibiotic therapy. Predefined subgroup 
analyses were conducted for the primary outcome based on age, 
diagnosis, APACHE II score, sepsis diagnosis, and negative res-
piratory culture status.
We determined that 476 patients would be needed in each 
group to detect a 10% difference in the primary composite out-
come of 30-day all-cause mortality or readmission for pneu-
monia, assuming a baseline incidence of 30%, with 90% power 
and a 2-sided alpha level of 0.05. Significance was defined as 
P < .05. All data were analyzed using IBM SPSS Statistics 25 for 
Windows.
RESULTS
A total of 11 860 admissions from 9717 unique patients were 
screened for inclusion (Figure 1). Of these, 10 048 admissions 
were excluded. The most common reasons for exclusion were 
failure to meet pneumonia criteria and meeting pneumonia cri-
teria within 48 hours of admission. The final cohort consisted 
of 1812 specific patient-admissions, 786 (43.4%) of which were 
identified as DE. The median age was 62 years and 41.3% (749 
of 1812) of patients were female. The median time from admis-
sion to diagnosis was 5 days, and 88.9% (1610 of 1812) of pa-
tients were in the ICU on day 0. A total of 60.8% of patients 
(1102 of 1812) had a diagnosis of HAP, 37.2% (410 of 1102) 
of which were ventilated, whereas the remaining patients had a 
diagnosis of VAP.
Overall, patient groups were well matched on baseline char-
acteristics (Table 1). Patients in the DE group were more likely 
to have VAP compared to those in the NDE group (43.4% vs 
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Table 1. Baseline Characteristics
Characteristic Total (n = 1812) DE (n = 786) NDE (n = 1026) P Value 
Age, years 62 [51–71] 62 [51–71] 61 [50–70] .095
Female 749 (41.3) 317 (40.3) 432 (42.1) .447
Race .197
 White 1314 (72.5) 556 (70.7) 758 (73.9)
 African American 409 (22.6) 194 (24.7) 215 (21.0)
 Other/unknown 89 (4.9) 36 (4.6) 53 (5.2)
Height, m 1.7 [1.6–1.8] 1.7 [1.6–1.8] 1.7 [1.6–1.8] .229
Weight, kg 81.2 [67.1–99.8] 80.7 [66.4–99.8] 81.5 [67.2–99.7] .860
BMI, kg/m2 27 [23–33] 27 [23–33] 27 [23–33] .634
Modified APACHE II score 13 [9–17] 13 [10–17] 12 [9–16] <.001
Location Diagnosed .110
 Medical ward 202 (11.1) 77 (9.8) 125 (12.2)
 ICU 1610 (88.9) 709 (90.2) 901 (87.8)
Charlson comorbidity index 4 [2–6] 3 [2–6] 4 [2–6] .045
Comorbid Conditions
 Heart failure 776 (42.8) 327 (41.6) 449 (43.8) .357
 Myocardial infarction 426 (23.5) 173 (22.0) 253 (24.7) .188
 Stroke 361 (19.9) 156 (19.8) 205 (20.0) .944
 Chronic obstructive pulmonary disease 334 (18.4) 134 (17.0) 200 (19.5) .183
 Liver disease 263 (14.5) 107 (13.6) 156 (15.2) .341
 Diabetes 495 (27.3) 210 (26.7) 285 (27.8) .616
 Renal disease 607 (33.5) 254 (32.3) 353 (34.4) .350
 Leukemia 198 (10.9) 71 (9.0) 127 (12.4) .024
 Lymphoma 83 (4.6) 41 (5.2) 42 (4.1) .257
 Cystic fibrosis 29 (1.6) 5 (0.6) 24 (2.3) .004
Transplant Status
 Solid organ transplant (non-lung) 40 (2.2) 19 (2.4) 21 (2.0) .595
 Lung transplant 50 (2.8) 18 (2.3) 32 (3.1) .286
 Bone marrow transplant 95 (5.2) 35 (4.5) 60 (5.8) .187
Immunosuppressive medications 248 (13.7) 84 (10.7) 164 (16.0) .001
Sepsis 1100 (60.7) 469 (59.7) 631 (61.5) .429
 Septic shock 778/1100 (70.7) 327/469 (69.7) 451/631 (71.5) .316
Number of vasopressors on day 0, mean ± SD 0.69 ± 0.84 0.66 ± 0.83 0.71 ± 0.85 .225
Lowest MAP on index date, mmHga 75 [64–87] 74 [63–87] 76 [65–87] .217
Neutropenia on day 0
 <1000 cells/µL 32 (1.8) 12 (1.5) 20 (1.9) .498
 <500 cells/µL 18 (1.0) 8 (1.0) 10 (1.0) .927
Tmax on index date, mean (SD)
a 37.0 [36.7–37.5] 37.0 [36.7–37.6] 37.0 [36.7–37.4] .019
WBC on index datea 11.5 [7.8–16.8] 11.5 [7.9–16.4] 11.6 [7.7–17.0] .845
Dialysis 122 (6.7) 57 (7.3) 65 (6.3) .440
Serum Creatinine, mg/dLb
 Admission 1.03 [0.75–1.45] 1.03 [0.72–1.46] 1.03 [0.77–1.44] .446
 Index date 0.99 [0.70–1.55] 0.95 [0.69–1.51] 1.02 [0.70–1.57] .278
Creatinine Clearance, mL/minb
 Admission 62 [41–84] 61 [40–86] 62 [43–82] .939
 Index date 58 [39–82] 58 [37–85] 58 [39–80] .814
Diagnosis
 HAP 1102 (60.8) 445 (56.6) 657 (64.0) .001
  Ventilated HAP 410 (37.2) 170 (38.2) 240 (36.5) .673
 VAP 710 (39.2) 341 (43.4) 369 (36.0) .001
Days from admission to diagnosis (range) 5 [3–10] (2–168) 5 [3–10] 5 [3–10] .271
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; DE, de-escalation; HAP, hospital-acquired pneumonia; ICU, intensive care unit; NDE, no 
de-escalation; MAP, mean arterial pressure; SD, standard deviation; WBC, white blood cell count.
NOTE: Results shown as no. (%) or median [interquartile range] unless otherwise indicated. 
aTmax data only available for 1727 patients; WBC available for 1571 patients; MAP available for 1803 patients.
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among patients in the DE group (13 DE vs 12 NDE; P < .001), 
whereas CCI scores were higher among patients in the NDE 
group (3 DE vs 4 NDE; P = .045). Patients in the DE group were 
less likely to carry diagnoses of leukemia or cystic fibrosis or 
have received immunosuppressive medications in prior 30 days. 
There was no difference between groups based on transplant 
status, septic shock status, or neutropenia.
The most commonly ordered antibiotics were vancomycin, 
cefepime, meropenem, and linezolid (Table 2). The median 
spectrum score on day 1 was 14. Spectrum score trends over 
time are shown in Figure 2 and Supplementary Figure 1. 
Patients receiving DE experienced a 65% and 44% reduction 
in anti-MRSA and anti-PSAR therapies by day 3, respectively 
(Supplementary Figure 2). Significantly more patients in the 
DE group had respiratory bacterial cultures completed com-
pared to those in the NDE group (56.6% vs 50.6%; P = .011). 
Accordingly, patients in the DE group were more likely to have 
respiratory cultures with a likely bacterial pathogen (50.8% vs 
39.3%; P < .001) and/or clinically insignificant flora (19.3% 
vs 14.8%) compared to patients in the NDE group. The most 
common bacteria isolated were S aureus, P aeruginosa, and 
Enterobacter spp at 38.6%, 17.7%, and 9.5%, respectively.
Primary and secondary outcomes are shown in Table 3. 
There was no difference between groups in the primary out-
come of 30-day composite treatment failure on bivariate 
analysis (35.0% DE vs 33.8% NDE; P = .604) or log-rank test 
(Supplementary Figure 3). There were also no differences in 
the individual components of the composite primary outcome, 
in-hospital mortality, 14-day all-cause mortality, readmission 
for any indication, or treatment re-escalation. However, pa-
tients in the DE group had fewer antibiotic days (median 9 vs 
11, P < .0001), episodes of C difficile (2.2% vs 3.8%, P = .046), 
and hospital days (median 20 vs 22 days, P = .006). Patients in 
the DE group also spent less time in the ICU and on a venti-
lator compared to patients in the NDE group. In addition, there 
were consistent trends towards reduced AKI and initiation of 
renal replacement therapy in patients in the DE group com-
pared to those in the NDE group.
Supplementary Table 2 shows the results of the multivariable 
Cox regression analysis. After controlling for confounding 
variables, including ventilator status and number of vasopres-
sors by day, DE was not found to be a significant predictor of 
30-day composite treatment failure (hazard ratio, 1.13; 95% 
confidence interval, 0.96–1.33). Statistically significant pre-
dictors of the primary outcome included modified APACHE 
II score, CCI, HAP status, septic shock, leukemia, and ven-
tilator status on day 3. Attainment of respiratory specimens 
positive for a likely pathogen was also a statistically significant 
predictor of the primary outcome. The prespecified subgroup 
analysis did not identify any differences between groups in 
terms of 30-day all-cause mortality or readmission for pneu-
monia (Supplementary Table 3).
There were 423 patients still in the cohort (did not discharge 
or die) on day 27 (Figure 2, Supplementary Table 4). Of these, 
243 of 423 (57.4%) remained on antibiotics of interest, with a 
median spectrum score of 9. Compared to the overall cohort, 
patients remaining on antibiotics on day 27 were numerically 
more likely to have leukemia (17.7% vs 10.9%), cystic fibrosis 
(2.9% vs 1.6%), coinfection (53.9% vs 34.0%), or receive immu-
nosuppressive medications (21.0% vs 13.7%) (Supplementary 
Table 5).
DISCUSSION
In this large study of 1812 patients with HAP and VAP, antibiotic 
DE identified using changes in spectrum scores was not asso-
ciated with 30-day composite treatment failure when compared 
to NDE. This lack of association persisted after controlling for 
confounding variables on multivariable Cox regression analysis 
and remained consistent among prespecified subgroups.
De-escalation is recommended following positive culture 
data (ie, narrowing to pathogen-directed therapy) and in clin-
ically stable patients following negative cultures [2]. Despite 
these recommendations, DE may not occur. A recent retrospec-
tive study found that DE rates ranged from 2% to 35% following 
negative cultures in patients with pneumonia among 164 US 
hospitals from 2010 to 2015, although DE in this study was de-
fined as cessation of both anti-MRSA and anti-PSAR therapies 
[21]. Similar to our study, a recent comprehensive systematic 
review and meta-analysis of 9 observational studies comprising 
2128 patients with pneumonia in the ICU found that DE was 
associated with shorter hospital stay but had no discernable 
impact on mortality, although all studies were assessed as 
low-quality evidence [22]. Additional studies published after 
this meta-analysis have also found similar mortality outcomes 
among patients who received DE versus those who did not [13, 
23, 24].
One difficulty in interpreting the DE literature is the wide 
range of definitions used, many of which are subjective and re-
quire chart review [22]. We opted to calculate spectrum scores 
using the modified ASI [15] and defined DE as a reduction in 
score on day 3 compared to day 1. Bohan et al [13] also used 
spectrum scores to define DE in a large retrospective cohort 
of veterans hospitalized with healthcare-associated pneu-
monia. Although the spectrum scoring methodology differed 
from ours, DE was similarly defined as a reduction in overall 
score. Likewise, there were no differences in clinical outcomes 
in patients who received DE versus those who did not [13]. In 
keeping both with traditional definitions of DE and antimicro-
bial stewardship program initiatives, patients in the DE group 
in our study had a 65% and 44% reduction in anti-MRSA and 
anti-PSAR therapies on day 3, respectively, contrasting starkly 
with the relatively unchanged utilization of these agents on day 
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Table 2. Antibiotic and Culture Data
Characteristic Total (n = 1812) DE (n = 786) NDE (n = 1026) P Value 
Baseline Antibiotics on Day 1
 Vancomycin 1012 (55.8) 481 (61.2) 531 (51.8) <.001
 Cefepime 951 (52.5) 445 (56.6) 506 (49.3) .002
 Meropenem 616 (34.0) 269 (34.2) 347 (33.8) .857
 Linezolid 468 (25.8) 218 (27.7) 250 (24.4) .104
 Azithromycin 278 (15.3) 164 (20.9) 114 (11.1) <.001
 Piperacillin-tazobactam 112 (6.2) 58 (7.4) 54 (5.3) .064
 Ceftriaxone 91 (5.0) 69 (8.8) 22 (2.1) <.001
 Gentamicin 22 (1.2) 18 (2.3) 4 (0.4) <.001
Antibiotics on Day 3
 Vancomycin 675 (37.3) 143 (18.2) 532 (51.9) <.001
 Cefepime 687 (37.9) 191 (24.3) 496 (48.3) <.001
 Meropenem 601 (33.2) 166 (21.1) 435 (42.4) <.001
 Linezolid 405 (22.4) 83 (10.6) 322 (31.4) <.001
 Azithromycin 167 (9.2) 44 (5.6) 123 (12.0) <.001
 Piperacillin-tazobactam 82 (4.5) 28 (3.6) 54 (5.3) .084
 Ceftriaxone 163 (9.0) 110 (14.0) 53 (5.2) <.001
 Gentamicin 13 (0.7) 3 (0.4) 10 (1.0) .138
Number of Antibiotics
 Day 1 (mean ± SD) 2 [2–3] 2 [2–3] (2.57 ± 0.8) 2 [2–2] (2.04 ± 0.7) <.001
 Day 3 2 [1–2] 1 [1–2] 2 [2–3] <.001
Anti-MRSA Antibiotic
 Day 1 1494 (82.5) 687 (87.4) 807 (78.7) <.001
 Day 3 1090 (60.2) 239 (30.4) 851 (82.9) <.001
Antipseudomonal Antibiotic
 Day 1 1670 (92.2) 729 (92.7) 941 (91.7) .418
 Day 3 1371 (75.7) 408 (51.9) 963 (93.9) <.001
Spectrum Score
 Admission 3 [0–13] 3 [0–13] 5 [0–12] .766
 Day 0 14 [11–16] 14 [11–16] 13 [12–16] .786
 Day 1 14 [12–16] 15 [12–18] 13 [10–15] <.001
 Day 3 12 [7–15] 7 [3–12] 15 [12–16] <.001
Respiratory Samples Ordered 964 (53.2) 445 (56.6) 519 (50.6) .011
 Positive for likely respiratory pathogen 523/964 (54.3) 257/445 (57.8) 266/519 (51.3) .043
MRSA Nasal Swab Sent 821 (45.3) 368 (46.8) 453 (44.2) .258
 Negative result 758/821 (92.3) 339/368 (92.1) 419/453 (92.5) .841
Respiratory Specimen Typea
 Sputum-like 631 (65.5) 308 (69.2) 323 (62.2) .023
 BAL 464 (48.1) 207 (46.5) 257 (49.5) .352
Respiratory clinically insignificant florab 304 (16.8) 152 (19.3) 152 (14.8) .011
Respiratory virus isolated 118 (12.2) 51 (11.5) 67 (12.9) .494
Respiratory yeast isolated 220 (22.8) 93 (20.9) 127 (24.5) .188
Respiratory mold isolated 23 (2.4) 5 (1.1) 18 (3.5) .017
Respiratory bacteria isolated 430 (44.6) 226 (50.8) 204 (39.3) <.001
 Staphylococcus aureus 166 (38.6) 81 (35.8) 85 (41.7) .215
 Methicillin-susceptible 83 (50.0) 42 (51.9) 41 (48.2) .641
 Methicillin-resistant 83 (50.0) 39 (48.1) 44 (51.8) .641
 Vancomycin-intermediate 2 (1.2) 0 2 (2.4) .497
 Pseudomonas aeruginosa 76 (17.7) 42 (18.6) 34 (16.7) .603
 Enterobacter spp 41 (9.5) 25 (11.1) 16 (7.8) .256
 Escherichia coli 37 (8.6) 24 (10.6) 13 (6.4) .117
 Klebsiella spp 34 (7.9) 16 (7.1) 18 (8.8) .503
 Haemophilus spp 28 (6.5) 14 (6.2) 14 (6.9) .779
 Stenotrophomonas maltophilia 25 (5.8) 10 (4.4) 15 (7.4) .195
 Serratia marcescens 23 (5.3) 14 (6.2) 9 (4.4) .412
 Streptococcus pneumoniae 16 (3.7) 7 (3.1) 9 (4.4) .472
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A drawback of retrospective research is the inherent selec-
tion bias present in treatment groups. For example, clinicians 
may not pursue DE in patients assessed as having a poor clin-
ical status. In our study, patients with cystic fibrosis or leukemia 
were less likely to be de-escalated, although these represented 
small subgroups. However, strong predictors of mortality, such 
as septic shock and APACHE II score, were well balanced be-
tween treatment groups. Patients in the DE group were also 
more likely to have a positive respiratory pathogen obtained, 
which was shown to be a significant predictor of 30-day com-
posite treatment failure. After controlling for these and other 
clinical parameters, such as ventilator status and number of 
vasopressors by day, there was no association between DE and 
the primary outcome.
One notable finding in this real-world study is the difference 
in respiratory culture data between comparison groups. Patients 
who had respiratory cultures ordered between days –1 and 3 
were more likely to have a pathogen identified and to receive 
DE, regardless of respiratory specimen type. It is interesting to 
note that obtaining MRSA nasal culture swabs was not associ-
ated with DE; however, this could be due in part to variations 
in the timing of swabs (eg, swabbing on admission vs on suspi-
cion of nosocomial pneumonia). Although these findings un-
derscore the importance of obtaining respiratory samples, there 
was also no difference in composite treatment failure in patients 
with culture-negative pneumonia (either due to negative cul-
tures or lack of cultures altogether). These data suggest that 
DE is safe in both circumstances and should be given strong 
consideration by clinicians managing patients with nosocomial 
pneumonia regardless of negative respiratory cultures.
The spectrum score-based methodology used in our study 
allows for objective, measurable, and reproducible identifica-
tion of DE. Spectrum scores, such as the modified ASI, may 
also prove useful for benchmarking, both internally (for assess-
ment of quality improvement projects) and externally (to com-
pare to other institutions and identify areas of opportunity). For 
example, Yarrington et al [25] deployed the ASI to understand 
antimicrobial use across space and time within their institution, 
noting that utilization of broad-spectrum agents increases over-
night and on weekends. Efforts are currently underway at our 
institution to incorporate the modified ASI into the electronic 



















9 9 9 9
7 7 7 7 7 7 7 6.5 6.5
6 6


























Median spectrum score DE
Number patients DE
Median spectrum score NDE
Number patients NDE
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Figure 2. Median spectrum scores day 0 to 28. DE, de-escalation; ICU, intensive care unit; NDE, no de-escalation.
Characteristic Total (n = 1812) DE (n = 786) NDE (n = 1026) P Value 
 Moraxella catarrhalis 8 (1.9) 5 (2.2) 3 (1.5) .570
 Proteus spp 7 (1.6) 6 (2.7) 1 (0.5) .077
 Streptococcus agalactiae 6 (1.4) 4 (1.8) 2 (1.0) .486
Blood Culture Sent 1270 (70.1) 557 (70.9) 713 (69.5) .527
 Positive for likely bacterial pathogen 105/1270 (8.3) 42/557 (7.5) 63/713 (8.8) .405
No respiratory or blood cultures sent day −1 to 3 366 (20.2) 151 (19.2) 215 (21.0) .359
Coinfection during admission 616 (34.0) 262 (33.3) 354 (34.5) .602
Abbreviations: BAL, bronchoalveolar lavage; DE, de-escalation; MRSA, methicillin-resistant Staphylococcus aureus; NDE, no de-escalation; SD, standard deviation. 
NOTE: Results shown as no. (%) or median [interquartile range] unless otherwise indicated.
aSputum-like = sputum, induced-sputum, and tracheal aspirates; BAL = washings and brushings.
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of antimicrobial burden and help identify patients that could be 
candidates for stewardship interventions.
Our study has several strengths. This is a large, contempo-
rary cohort, which reflects current clinical practices and pro-
vides adequate power to minimize type II error. We screened 
patients using strict enrollment criteria for nosocomial pneu-
monia, notably excluding those who met these criteria too early 
in their hospital course. We also used a novel yet simple meth-
odology to define antibiotic DE, which is easily reproducible 
and provides a comprehensive picture of the overall antimicro-
bial pressure on a patient’s normal flora. Finally, we were able to 
collect and control for many confounding variables, including 
immunosuppressive medications, ventilator status by day, and 
number of vasopressors by day, utilizing a multivariable time-
to-event regression analysis.
Our study also has limitations. First, as a single-center retro-
spective review, this study is subject to selection bias. Although 
our groups were relatively well matched at baseline, there 
may have been differences between groups that were unac-
counted for, thereby limiting the capacity to determine cau-
sality. Furthermore, these results may not be generalizable to 
other institutions with different patient populations and/or 
practice models. For example, all patients in this cohort were 
receiving either anti-MRSA or anti-PSAR antibiotics on day 
Table 3. Primary and Secondary Outcomes
Outcome Total (n = 1812) DE (n = 786) NDE (n = 1026) P Value 
Primary Outcome
Composite treatment failurea 622 (34.3) 275 (35.0) 347 (33.8) .604
Secondary Outcomes
30-day all-cause mortality 571 (31.5) 252 (32.1) 319 (31.1) .660
Readmission for pneumonia within 30 days of day 0 65 (3.6) 28 (3.6) 37 (3.6) .960
Readmission for pneumonia within 30 days of hospital discharge 97 (5.4) 37 (4.7) 60 (5.8) .285
Readmission any within 30 days of hospital discharge 382 (21.1) 162 (20.6) 220 (21.4) .667
Treatment re-escalation 416 (23.0) 191 (24.3) 225 (21.9) .234
In-hospital mortality 517 (28.5) 212 (27.0) 305 (29.7) .198
14-day mortality 407 (22.5) 180 (22.9) 227 (22.1) .695
Days from index to expirationc 16 [8–58] 15 [7–53] 16 [8–59] .165
Hospital Length of Stay, Days 21 [13–35] 20 [13–33] 22 [14–36] .006
 ICU daysd 12.8 [7.0–22.0] 11.8 [6.9–20.2] 13.6 [7.1–23.9] .004
Days ventilatede 10 [5–17] 9 [5–15] 10 [5–18] .019
Ventilator-free days, percentagee 54.2 [28.6–72.7] 55.0 [30.0–72.7] 53.1 [26.7–72.8] .496
Antibiotic days from day 0 to 28 10 [6–17] 9 [6–15] 11 [7–18] <.001
AKI to day 21b
 Stage I 546 (35.5) 230 (34.4) 316 (36.4) .423
 Stage II 167 (10.9) 67 (10.0) 100 (11.5) .352
 Stage III 184 (12.0) 70 (10.5) 114 (13.1) .112
AKI to Day 1 to Day 7b
 Stage I 421 (27.4) 169 (25.3) 252 (29.0) .104
 Stage II 118 (7.7) 47 (7.0) 71 (8.2) .404
 Stage III 132 (8.6) 52 (7.8) 80 (9.2) .321
AKI to Day 8 to Day 14b
 Stage I 290 (18.9) 108 (16.2) 182 (21.0) .017
 Stage II 89 (5.8) 31 (4.6) 58 (6.7) .090
 Stage III 57 (3.7) 18 (2.7) 39 (4.5) .065
AKI to Day 15 to Day 21b
 Stage I 151 (9.8) 55 (8.2) 96 (11.1) .065
 Stage II 48 (3.1) 22. (3.3) 26 (3.0) .739
 Stage III 28 (1.8) 10 (1.5) 18 (2.1) .402
New RRTb 163 (10.6) 61 (9.1) 102 (11.8) .098
Clostridioides difficile infection index to 90 days 56 (3.0) 17 (2.2) 39 (3.8) .046
Additional vasopressor started days 4 through 7 202 (11.1) 75 (9.5) 127 (12.4) .057
Abbreviations: AKI, acute kidney injury; DE, de-escalation; ICU, intensive care unit; NDE, no de-escalation; RRT, renal replacement therapy; SD, standard deviation.
NOTE: Results shown as no. (%) or median [interquartile range] unless otherwise indicated.
a30-day all-cause mortality or readmission for pneumonia within 30 days index pneumonia date.
bOf 1372 patients without dialysis on admission or receipt of RRT before day 0: 607 in DE group and 765 in NDE group.
cOf 857 patients with known expiration dates: 365 in DE and 492 in NDE.
dOf 1733 patients with any time in the ICU: 762 in DE and 971 in NDE.
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1, which may have made it relatively “easy” to be de-escalate. 
Second, using changes in spectrum scores to identify DE may 
lack specificity, because the difference in scores between 2 days 
can be influenced by minor changes in antibiotic orders (eg, 
one-time dose of aminoglycoside on day 1 and not continued 
on day 3). We also assessed antibiotic orders, not administra-
tions. Although it is possible that some antibiotic orders were 
“counted” despite having never been administered, we con-
sidered such events rare enough to have minimal impact on 
the results. Furthermore, calculation of the modified ASI was 
consistent between treatment groups, and the differences in 
the groups remained evident over time as shown in Figure 2. 
Third, approximately one third of the patients in this study had 
coinfections, which may have impacted the ability to de-esca-
late; however, groups were well matched at baseline regarding 
number and type of coinfections (Supplementary Tables 6 and 
7). Fourth, only a subset of vasopressors (norepinephrine, vas-
opressin, and dobutamine) were included. Fifth, most patients 
in this cohort were in the ICU, so results may not be general-
izable to nosocomial pneumonia in noncritically ill patients. 
Finally, interpretation of chest radiographs and clinical criteria 
for establishing a diagnosis of pneumonia were determined by 
treating physicians at the time of hospital admission. Although 
this could introduce heterogeneity in terms of pneumonia diag-
noses, we believe such heterogeneity reflects real-world cir-
cumstances and is therefore generalizable to other institutions.
CONCLUSIONS
Overuse of broad-spectrum antimicrobials remains a pressing 
public health problem. Although it is known that improper em-
piric antibiotic coverage is associated with increased mortality 
in patients with nosocomial pneumonia, excessive broad-spec-
trum antibiotic coverage carries risks of its own. Our findings 
suggest that antibiotic DE is not associated with composite treat-
ment failure, but instead it may be associated with shorter hos-
pitalizations and reduced rates of C difficile infection. Further 
studies are needed to fully understand the utility of spectrum 
score-based determinations of antibiotic DE.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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